Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Julphar
Cerilliant
Novartis
Chubb
Accenture
Baxter
Argus Health
McKesson
Cipla

Generated: October 22, 2017

DrugPatentWatch Database Preview

PLAVIX Drug Profile

« Back to Dashboard

What is the patent landscape for Plavix, and when can generic versions of Plavix launch?

Plavix is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in forty-three countries and eight supplementary protection certificates in six countries.

The generic ingredient in PLAVIX is clopidogrel bisulfate. There are fifty-three drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the clopidogrel bisulfate profile page.

Summary for Tradename: PLAVIX

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list10
Bulk Api Vendors: see list120
Clinical Trials: see list178
Patent Applications: see list2,071
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PLAVIX at DailyMed

Pharmacology for Tradename: PLAVIX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997ABRXYesNo► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-002Sep 20, 2007ABRXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997ABRXYesNo► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-002Sep 20, 2007ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PLAVIX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997► Subscribe► Subscribe
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997► Subscribe► Subscribe
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-001Nov 17, 1997► Subscribe► Subscribe
Sanofi Aventis Us
PLAVIX
clopidogrel bisulfate
TABLET;ORAL020839-002Sep 20, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for PLAVIX

Drugname Dosage Strength RLD Submissiondate
clopidogrel bisulfateTablets300 mgPlavix3/4/2009

International Patent Family for Tradename: PLAVIX

Country Document Number Estimated Expiration
Norway327161► Subscribe
Brazil9911219► Subscribe
Eurasian Patent Organization200001187► Subscribe
Czech Republic20004637► Subscribe
Yugoslavia77700► Subscribe
Austria222256► Subscribe
Algeria2817► Subscribe
New Zealand507914► Subscribe
Canada2334870► Subscribe
Argentina014854► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PLAVIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/001United Kingdom► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGEN SULPHATE, THE DEXTROROTATORY ISOMER OF ALPHA-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRID-5-YL)(2-CHLOROPHENYL) METHYL ACETATE AS THE HYDROGEN SULPHATE SALT; REGISTERED: UK EU/1/98/069/001 19980715; UK EU/1/98/069/002 19980715; UK EU/1/98/069/003 19980715
90035-0 98910359Sweden► SubscribePRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715
C0036Belgium► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
/1998Austria► SubscribePRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
90035Sweden► SubscribePRODUCT NAME: PLAVIX-CLOPIDOGREL; REG. NO/DATE: EU/1/98/069/001 19980715
90002Netherlands► SubscribePRODUCT NAME: CLOPIDOGREL WATERSTOFSULFAAT; REGISTRATION NO/DATE: EU 1/98/069/001 - EU 1/98/069/003 19980715
8C0045Belgium► SubscribePRODUCT NAME: CLOPIDOGREL; REGISTRATION NO/DATE: EU/1/98/069/001 19980715
C0036France► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Moodys
Novartis
Cerilliant
QuintilesIMS
Cipla
Chinese Patent Office
Merck
Farmers Insurance
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot